This Article Full Text Full Text (PDF) All Versions of this Article: 90/3/1775    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benvenuti, S. Articles by Peri, A. Search for Related Content PubMed PubMed Citation Articles by Benvenuti, S. Articles by Peri, A. Related Collections Female Endocrinology Neuroendocrinology and Pituitary

Estrogen and Selective Estrogen Receptor Modulators Exert Neuroprotective Effects and Stimulate the Expression of Selective Alzheimer’s Disease Indicator-1, a Recently Discovered Antiapoptotic Gene, in Human Neuroblast Long-Term Cell Cultures

Endocrine Unit (S.B., P.L., E.F., M.S., A.P.) and Clinical Biochemistry Unit (S.G.), Department of Clinical Physiopathology, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative, and Neoplastic Disorders, University of Florence; and Department of Anatomy, Histology, and Forensic Medicine (G.B.V.), University of Florence, 50139 Florence, Italy

Address all correspondence and requests for reprints to: Alessandro Peri, M.D., Ph.D., Endocrine Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy. E-mail: a.peri{at}dfc.unifi.it.

According to the fact that Alzheimer’s disease (AD) is more common in postmenopausal women, estrogen treatment has been proposed. Experimental studies, still mostly performed using animal models, demonstrated that estrogen exerts neuroprotective effects. We previously established neuroblast long-term cell cultures from human fetal olfactory epithelium. In the present study, we addressed the role of estrogen in these unique human cells, which express both the estrogen receptor (ER)- and ERß. We found that 17ß-estradiol (17ßE₂) and the selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen exerted neuroprotective effects, which were independent of cell proliferation, by increasing resistance against ß-amyloid-induced toxicity, with the exception of the highest concentrations of raloxifene (10 and 100 nM). In addition, 17ßE₂ exposure protected from oxidative stress, reduced apoptosis, and increased the expression of the catalytic subunit of telomerase. Furthermore, we evaluated by quantitative real-time RT-PCR whether estrogen/SERMs modulate the expression of the recently discovered seladin-1 (selective AD indicator-1) gene, which exerts neuroprotective effects and is down-regulated in AD-vulnerable brain regions. 17ßE₂ (100 pM to 100 nM) and SERMs (1 nM) significantly increased the amount of seladin-1 mRNA. Conversely, 10 and 100 nM raloxifene reduced the expression of seladin-1. The effect of estrogen appears mainly mediated by ER because the selective ER agonist propylpyrazole-triol determined a much greater increase of seladin-1 expression than the ERß agonist diarylpropionitrile. Our results add new evidence, using human neuronal cells, for a beneficial effect of estrogen in preventing neurodegenerative diseases and suggest for the first time that seladin-1 may mediate this effect.

This article has been cited by other articles:

				S. Tapia-Gonzalez, P. Carrero, O. Pernia, L. M Garcia-Segura, and Y. Diz-Chaves Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs J. Endocrinol., July 1, 2008; 198(1): 219 - 230. [Abstract] [Full Text] [PDF]

				S Benvenuti, P Luciani, I Cellai, C Deledda, S Baglioni, R Saccardi, S Urbani, F Francini, R Squecco, C Giuliani, et al. Thyroid hormones promote cell differentiation and up-regulate the expression of the seladin-1 gene in in vitro models of human neuronal precursors J. Endocrinol., May 1, 2008; 197(2): 437 - 446. [Abstract] [Full Text] [PDF]

				K. Kuehnle, A. Crameri, R. E. Kalin, P. Luciani, S. Benvenuti, A. Peri, F. Ratti, M. Rodolfo, L. Kulic, F. L. Heppner, et al. Prosurvival Effect of DHCR24/Seladin-1 in Acute and Chronic Responses to Oxidative Stress Mol. Cell. Biol., January 15, 2008; 28(2): 539 - 550. [Abstract] [Full Text] [PDF]

				P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, et al. Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis in Growth Hormone-Secreting and Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6156 - 6161. [Abstract] [Full Text] [PDF]

				O. Imamov, G.-J. Shim, M. Warner, and J.-A. Gustafsson Estrogen Receptor beta in Health and Disease Biol Reprod, November 1, 2005; 73(5): 866 - 871. [Abstract] [Full Text] [PDF]

				C. E. GLEASON, C. M. CARLSSON, S. JOHNSON, C. ATWOOD, and S. ASTHANA Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations Ann. N.Y. Acad. Sci., June 1, 2005; 1052(1): 93 - 115. [Abstract] [Full Text] [PDF]